Stryker (NYSE:SYK – Get Free Report) had its target price hoisted by investment analysts at Stifel Nicolaus from $400.00 to $440.00 in a report released on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the medical technology company’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 12.68% from the stock’s current price.
A number of other research analysts have also issued reports on SYK. JMP Securities reissued a “market perform” rating on shares of Stryker in a research note on Tuesday, January 7th. Evercore ISI boosted their target price on shares of Stryker from $380.00 to $384.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Canaccord Genuity Group boosted their target price on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday. UBS Group upped their price target on shares of Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 30th. Finally, Citigroup upped their price target on shares of Stryker from $411.00 to $450.00 and gave the stock a “buy” rating in a research note on Wednesday, December 11th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $416.40.
Read Our Latest Report on Stryker
Stryker Price Performance
Stryker (NYSE:SYK – Get Free Report) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 16.34% and a return on equity of 23.07%. During the same quarter in the prior year, the firm posted $3.46 earnings per share. On average, sell-side analysts anticipate that Stryker will post 12.06 EPS for the current year.
Insider Activity
In other news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by company insiders.
Institutional Investors Weigh In On Stryker
A number of large investors have recently made changes to their positions in the company. Blue Zone Wealth Advisors LLC raised its holdings in shares of Stryker by 1.2% during the fourth quarter. Blue Zone Wealth Advisors LLC now owns 20,912 shares of the medical technology company’s stock valued at $7,529,000 after acquiring an additional 243 shares during the period. WD Rutherford LLC increased its stake in Stryker by 1.6% in the 4th quarter. WD Rutherford LLC now owns 10,630 shares of the medical technology company’s stock valued at $3,827,000 after buying an additional 163 shares during the period. Strategic Financial Concepts LLC acquired a new position in Stryker in the 4th quarter valued at approximately $55,769,000. Principal Securities Inc. increased its stake in Stryker by 21.5% in the 4th quarter. Principal Securities Inc. now owns 7,584 shares of the medical technology company’s stock valued at $2,731,000 after buying an additional 1,340 shares during the period. Finally, Everhart Financial Group Inc. increased its stake in Stryker by 2.4% in the 4th quarter. Everhart Financial Group Inc. now owns 3,245 shares of the medical technology company’s stock valued at $1,168,000 after buying an additional 75 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Featured Articles
- Five stocks we like better than Stryker
- Insider Trading – What You Need to Know
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- What is a Secondary Public Offering? What Investors Need to Know
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.